

HETEROCYCLIC COMPOUNDS FROM 3,4-DIAMINO-DIMETHYLAMINO-1-METHYLPYRAZOLO[3,4-*d*]PYRIMIDINE: APPROACH TO NOVEL *ORTHO*- AND *PERI*-FUSED HETEROCYCLIC RING SYSTEM

Zhijun Wang and Richard Neidlein*


Pharmazeutisch-Chemisches Institut der Universität Heidelberg
Im Neuenheimer Feld 364, D-69120 Heidelberg, Germany

Abstract - Treatment of 3,4-diamino-6-dimethylamino-1-methylpyrazolo[3,4-*d*]pyrimidine (**4**) with acid chlorides (**5a-h**) led to formation of 3-substituted carbonylamino-4-amino-6-dimethylamino-1-methylpyrazolo[3,4-*d*]pyrimidines (**6a-h**), which reacted with *N,N*-dimethylformamide dimethyl acetal (**7**) to yield 4-dimethylaminoazomethinopyrazolo[3,4-*d*]pyrimidine derivatives (**8a-c**). Approach to novel *ortho*- and *peri*-fused tricyclic heterocyclic system, namely, 1,2,3,5,6,8-hexaazaacenaphthylene derivatives (**11**, **12**) is also reported.

INTRODUCTION

Ketene acetals became known already in 1907, but the first dicyanoketene acetal was reported by W. J. Middleton *et al.* fifty years later as they systematically studied synthesis and reactions of tetracyanoethylene.¹ At the same time, they reported that when dicyanoketene ethylene acetal was treated with an excess of ammonia, both of the alkoxy groups were replaced and 1,1-diamino-2,2-dicyanoethylene (**1**) was formed; the first synthesis of dicyanoketene² and its chemical reactions were done 1980. The only reaction of **1** studied by W. J. Middleton *et al.* was its condensation reaction with ethyl malonate to give 2-dicyanomethylene-4,6-dioxo-hexahydropyrimidine.^{1b} All dicyanoketene acetals were prepared from tetracyanoethylene by method of Middleton *et al.*¹ till 1988, when D. Kikelj in our group developed another convenient method to synthesize dicyanoketene ethylene acetal from sodium salt of malonodinitrile and 2-chlorethyl chloroformate in acetonitrile.³ This prompted us to investigate the utilities of **1** in heterocyclic organic synthesis. Using **1** as starting material we have recently synthesized a variety of heterocyclic compounds covering pyrimidines,⁴ pyrazolo[3,4-*d*]pyrimidines,⁵ pyrimido[4,5-*d*]pyrimidines⁶ and a novel *ortho*- and *peri*-fused tricyclic heterocyclic ring system in which a diazepine ring is *ortho*- and *peri*-fused to a pyrimido[4,5-*d*]pyrimidine skeleton.⁶ As continuation of our investigation, we describe in the present paper preparation of a series of pyrazolo[3,4-*d*]pyrimidine derivatives (**6a-h**, **8a-c**, **9a-b**, **10**) and approach to a novel *ortho*- and *peri*-fused tricyclic heterocyclic ring system, namely, 1,2,3,5,6,8-hexaazaacenaphthylene derivatives (**11**, **12**) from 3,4-diamino-6-dimethylamino-1-methylpyrazolo[3,4-*d*]pyrimidine (**4**) which is easily available from 1,1-diamino-2,2-dicyanoethylene (**1**) (as shown in Scheme 1).


Scheme 1



RESULTS AND DISCUSSION

Treatment of 3,4-diamino-6-dimethylamino-1-methylpyrazolo[3,4-*d*]pyrimidine (**4**) with acid chlorides (**5a-h**) in acetonitrile (or chloroform) afforded 3-substituted carbonylaminopyrazolo[3,4-*d*]pyrimidine derivatives (**6a-h**) (as shown in Scheme 2). It was beyond our expectation that only one of

Scheme 2



the amino groups in **4** reacted, even though acid chloride was excessive. The attempt to amidate the rest amino group in **6a** with acetyl chloride, acetic anhydride and trifluoroacetic anhydride was not successful. We could not obtain satisfactory crystals of **6** for X-Ray diffraction study to confirm their structures. But after comparing the $^{13}\text{C-NMR}$ spectra of **4** with **6a** (see Figure 1), it is not difficult to find that the

amino group at 3- position was amidated. Thus, besides the C-atom signals of anisoyl group [δ = 55.5 (-, OCH₃), 114.1 (-, C-3'), 125.4 (+, C-1'), 129.5 (-, C-2'), 163.1 (+, C-4'), 166.5 (+, C=O) ppm] the only obvious difference is that the signal for C-3 in **4** at δ = 147.2 (+) ppm⁵ (Figure 1a) vanished and at the meanwhile a new signal at δ = 137.4 (+) ppm appeared (Figure 1b). That the amino group at 3- position is more reactive than the other one is in accordance with our previous observation.⁵

Because of its high reactivity, *N,N*-dimethylformamide dimethyl acetal (**7**) is widely used for heterocyclic synthesis.^{7,8} **7** reacted with **6a-c** in toluene under reflux to yield 4-dimethylamino-azomethinopyrazolo[3,4-*d*]pyrimidine derivatives (**8a-c**) (see Scheme 2). When **4** was treated with one mole **7** in toluene at 90°C for 7 h, monoazomethino substituted pyrazolo[3,4-*d*]pyrimidine derivatives (**9a-b**) were formed in yields of 63.0% and 17.2% respectively (as shown in Scheme 3). This indicates also that the amino group at 3- position is more reactive as mentioned above. Treatment of an excess of **7** with **4** provided **10**.






Figure 1: a) 62.89 MHz ¹³C-NMR spectrum of **4** in DMSO-*d*₆
 b) 62.89 MHz ¹³C-NMR spectrum of **6a** in CDCl₃

Previously we attempted to synthesize *ortho*- and *peri*-fused tricyclic heterocyclic compounds from **4** and aldehydes, but no expected products were obtained.⁵ Treatment of **9a**, **10** and **8a** in xylene under reflux led to no cyclization, even though dimethylamino-substituent in dimethylaminoazomethino group is a relative good leaving group. After treatment of **6a** with POCl₃ under reflux for 3.5 h, 1,5-dihydro-7-dimethylamino-5*H*-1-methyl-4-(4-methoxyphenyl)-1,2,3,5,6,8-hexaazaacenaphthylene (**11**) was isolated in yield of 6.2% (see Scheme 4). Its ¹H-NMR spectrum shows that the NH signals [at δ = 6.31 (s, 2H, NH₂), 8.97 (s, 1H, CONH) ppm] of **6a** disappeared and a new NH signal at δ = 5.54 (s, 1H) ppm emerged, which indicated the formation of cyclization. As shown in Scheme 5, **4** reacted with ethyl chloroformate in acetonitrile at room temperature to yield 7-dimethylamino-1-methyl-1,3,5-trihydro-1,2,3,5,6,8,-hexaazaacenaphthylen-4(3,5*H*)-one (**12**) (23.6%). The absorption of C=O (ν = 1719 cm⁻¹) in its IR spectrum and the NH signals [δ = 7.09 (s, 1H), 10.04 (s, 1H) ppm] in ¹H-NMR spectrum provided evidences for the structure of **12**.


Scheme 3



Scheme 4



Scheme 5



In summary, using 3,4-diamino-6-dimethylamino-1-methylpyrazolo[3,4-*d*]pyrimidine (**4**) as educt a

variety of substituted pyrazolo[3,4-*d*]pyrimidine derivatives were prepared, a novel *ortho*- and *peri*-fused tricyclic heterocyclic ring system, namely, 1,2,3,5,6,8-hexaazaacenaphthylene was accessible.

EXPERIMENTAL

Melting points were determined on a Reichert hot stage microscope and are uncorrected. IR spectra were measured with a Perkin-Elmer spectrophotometer 283 using potassium bromide and are given as cm^{-1} . ^1H - and ^{13}C -NMR spectra were recorded on either a Bruker WM-250 (^1H -NMR: 250.13 MHz, ^{13}C -NMR: 62.89 MHz), Bruker WM-360 (^1H -NMR: 360 MHz, ^{13}C -NMR: 90.56 MHz) or a Varian XL 300 (^1H -NMR: 299.95 MHz, ^{13}C -NMR: 75.43 MHz) spectrometer in DMSO-d_6 or CDCl_3 . The chemical shifts are reported in parts per million (ppm) downfield from internal tetramethylsilane. Electron impact MS spectra were obtained on a Varian MAT 311A instrument. Element analyses were performed on a Heraeus Vario EL CHNS apparatus.

General procedure for the preparation of 6a-h:

A solution of **4** (0.31 g, 1.5 mmol), triethyl amine (0.3 mL, 2.25 mmol) and corresponding acid chloride (**5a-h**) (1.75 mmol) in water-free acetonitrile (60 mL) was stirred at rt for 24-125 h. After removal of the solvent under reduced pressure the residue was chromatographed on a silica column (70-230 mesh) using ethyl acetate/petroleum ether (3:1) as eluent to give **6a-h**.

4-Amino-6-dimethylamino-3-[(4-methoxybenzoyl)amino]-1-methylpyrazolo[3,4-*d*]pyrimidine (6a) (82.5%). mp 224-227°C (ethyl acetate). IR (KBr): 3314, 3140 (NH); 1665 (C=O); 1632, 1605, 1546 (C=C, C=N); 1395; 1257. ^1H -NMR (250.13 MHz, CDCl_3): δ = 3.13 (s, 6H, $\text{N}(\text{CH}_3)_2$); 3.70 (s, 3H, NCH_3); 3.86 (s, 3H, OCH_3); 6.31 (s, 2H, NH_2); 6.94 (dd, J = 6.9, 2.1 Hz, 2H, H-3'); 7.91 (dd, J = 6.9, 2.1 Hz, 2H, H-2'), 8.97 (s, 1H, CONH). ^{13}C -NMR (62.89 MHz, CDCl_3): δ = 32.7 (-, NCH_3); 37.1 (-, $\text{N}(\text{CH}_3)_2$); 55.5 (-, OCH_3); 89.2 (+, C-3a); 114.1 (-, C-3'); 125.4 (+, C-1'); 129.5 (-, C-2'); 137.4 (+, C-3); 157.5 (+, C-7a); 158.6 (+, C-4); 161.6 (+, C-6); 163.1 (+, C-4'); 166.5 (+, CONH). MS m/z (%): $[\text{M}+1]^+$: 342 (16); M^+ : 341 (75); 135 (100); 107 (12); 92 (12); 77 (25). Anal. Calcd for $\text{C}_{16}\text{H}_{19}\text{N}_7\text{O}_2$: C, 56.30; H, 5.61; N, 28.72. Found: C, 56.45; H, 5.76; N, 28.47.

4-Amino-6-dimethylamino-3-[(furan-2-carbonyl)amino]-1-methylpyrazolo[3,4-*d*]pyrimidine (6b) (60.2%). mp 171°C (ethyl acetate). IR (KBr): 3457, 3366, 3172 (NH); 1689 (C=O); 1662, 1640, 1588, 1569 (C=C, C=N); 1397; 1269; 864; 753. ^1H -NMR (250.13 MHz, CDCl_3): δ = 3.14 (s, 6H, $\text{N}(\text{CH}_3)_2$); 3.77 (s, 3H, NCH_3); 6.34 (s, 2H, NH_2); 6.57 (dd, J = 3.5, 1.9 Hz, 1H, H-4'); 7.28 (t, J = 4.2 Hz, 1H, H-3'); 7.54 (t, J = 1.1 Hz, 1H, H-5'); 8.80 (s, 1H, CONH). ^{13}C -NMR (90.56 MHz, CDCl_3): δ = 32.8 (-, NCH_3); 37.0 (-, $\text{N}(\text{CH}_3)_2$); 88.9 (+, C-3a); 112.8 (-, C-4'); 116.6 (-, C-3'); 136.0 (+, C-3); 145.3 (-, C-5'); 146.8 (+, C-2'); 157.1 (+, C-7a); 157.4 (+, C-4); 158.4 (+, C-6); 161.5 (+, CONH). MS m/z (%): $[\text{M}+1]^+$: 302 (15); M^+ : 301 (100); 286 (22); 272 (20); 95 (58); 71 (10); 44 (8). Anal. Calcd for $\text{C}_{13}\text{H}_{15}\text{N}_7\text{O}_2$: C, 51.82; H, 5.02; N, 32.54. Found: C, 51.48; H, 5.18; N, 32.05. HRMS: Calcd for $\text{C}_{13}\text{H}_{15}\text{N}_7\text{O}_2$: 301.1286. Found: 301.1285.

4-Amino-6-dimethylamino-1-methyl-3-[(thiophene-2-carbonyl)amino]pyrazolo[3,4-*d*]pyrimidine (6c) (61.5%). mp 229°C (ethyl acetate). IR (KBr): 3440, 3329, 3249 (NH); 1671 (C=O); 1641, 1611, 1553 (C=C, C=N); 1393; 1266; 785; 715. ¹H-NMR (250.13 MHz, CDCl₃): δ= 3.12 (s, 6H, N(CH₃)₂); 3.69 (s, 3H, NCH₃); 6.72 (s, 2H, NH₂); 7.23 (t, J= 4.8 Hz, 1H, H-4'); 7.90 (d, J= 4.5 Hz, 1H, H-5'); 8.12 (d, J= 3.3 Hz, 1H, H-3'); 10.85 (s, 1H, CONH). ¹³C-NMR (90.56 MHz, CDCl₃): δ= 32.4 (-, NCH₃); 36.6 (-, N(CH₃)₂); 89.7 (+, C-3a); 128.3 (-, C-4'); 130.3 (-, C-5'); 132.6 (-, C-3'); 136.6 (+, C-3); 138.4 (+, C-2'); 156.5 (+, C-7a); 157.8 (+, C-4); 161.1 (+, C-6); 161.5 (+, CONH). MS m/z (%): [M+1]⁺: 318 (13); M⁺: 317 (82); 302 (16); 288 (17); 111 (100); 71 (9); 44 (6). HRMS: Calcd for C₁₃H₁₅N₇O₂: 317.1058. Found: 317.1057.

4-Amino-3-[(4-chlorobenzoyl)amino]-6-dimethylamino-1-methylpyrazolo[3,4-*d*]pyrimidine (6d) (60.9%). mp 228°C (ethyl acetate). IR (KBr): 3415, 3293, 3219 (NH); 1657 (C=O); 1636, 1600, 1570, 1545 (C=C, C=N); 1393; 1088; 903; 850; 788. ¹H-NMR (250.13 MHz, DMSO-*d*₆): δ= 3.12 (s, 6H, N(CH₃)₂); 3.70 (s, 3H, NCH₃); 6.68 (s, 2H, NH₂); 7.60 (d, J= 8.6 Hz, 2H, H-3'); 8.06 (d, J= 8.6 Hz, 2H, H-2'); 10.79 (s, 1H, CONH). ¹³C-NMR (62.89 MHz, DMSO-*d*₆): δ= 32.5 (-, NCH₃); 36.7 (-, N(CH₃)₂); 89.9 (+, C-3a); 128.4 (-, C-3'); 129.9 (-, C-2'); 132.1 (+, C-1'); 136.9, 137.0 (2+, C-3, C-4'); 156.5 (+, C-7a); 157.7 (+, C-4); 161.2 (+, C-6); 165.9 (+, CONH). MS m/z (%): [M+2]⁺: 347 (18); M⁺: 345 (62); 330 (12); 316 (16); 141 (31); 139 (100); 111 (25); 71 (10); 44 (6). Anal. Calcd for C₁₅H₁₆N₇OCl: C, 52.10; H, 4.66; N, 28.35. Found: C, 52.30; H, 4.89; N, 27.99. HRMS: Calcd for C₁₅H₁₆N₇OCl: 345.1105. Found: 345.1107.

4-Amino-6-dimethylamino-1-methyl-3-[(*p*-methylbenzoyl)amino]pyrazolo[3,4-*d*]pyrimidine (6e) (64.6%). mp 102-105°C (ethyl acetate). IR (KBr): 3415, 3300, 3239 (NH); 1671 (C=O); 1648, 1609, 1575, 1549 (C=C, C=N); 1395; 1284; 1266; 903; 786. ¹H-NMR (250.13 MHz, CDCl₃): δ= 2.42 (s, 3H, CH₃); 3.13 (s, 6H, N(CH₃)₂); 3.72 (s, 3H, NCH₃); 7.27 (d, J= 8.0 Hz, 2H, H-3'); 7.83 (d, J= 8.2 Hz, 2H, H-2'); 8.83 (s, 1H, CONH). ¹³C-NMR (90.56 MHz, CDCl₃): δ= 21.6 (-, CH₃); 32.7 (-, NCH₃); 37.0 (-, N(CH₃)₂); 89.1 (+, C-3a); 127.5 (-, C-2'); 129.5 (-, C-3'), 130.1 (+, C-1'), 137.1 (+, C-3); 143.3 (+, C-4'); 157.4 (+, C-7a); 158.5 (+, C-4); 161.5 (+, C-6); 166.9 (+, CONH). MS m/z (%): [M+1]⁺: 326 (13); M⁺: 325 (60); 296 (8); 119 (100); 91 (33). Anal. Calcd for C₁₆H₁₉N₇O: C, 59.06; H, 5.89; N, 30.13. Found: C, 58.80; H, 6.19; N, 29.97. HRMS: Calcd for C₁₆H₁₉N₇O: 325.1649. Found: 325.1647.

4-Amino-3-benzylcarbonylamino-6-dimethylamino-1-methylpyrazolo[3,4-*d*]pyrimidine (6f) (59.1%). mp 188-189°C (ethyl acetate). IR (KBr): 3426, 3308, 3217 (NH); 1653 (C=O); 1600, 1576, 1542 (C=C, C=N); 1393; 787; 738; 702. ¹H-NMR (250.13 MHz, CDCl₃): δ= 3.16 (s, 6H, N(CH₃)₂); 3.68 (s, 3H, NCH₃); 3.76 (s, 2H, CH₂Ph); 6.17 (s, 2H, NH₂); 7.26-7.37 (m, 5H, H_{arom.}); 8.23 (s, 1H, CONH). ¹³C-NMR (62.89 MHz, CDCl₃): δ= 32.6 (-, NCH₃); 36.9 (-, N(CH₃)₂); 43.9 (+, CH₂Ph); 88.9 (+, C-3a); 127.8 (-, C-4'); 129.2 (-, C-3'), 129.4 (-, C-2'); 133.6 (+, C-1'), 136.6 (+, C-3); 157.3 (+, C-7a); 158.3 (+, C-4); 161.5 (+, C-6); 171.0 (+, CONH). MS m/z (%): [M+1]⁺: 326 (24); M⁺: 325 (100); 234 (48); 207 (89); 192 (29); 178 (24); 164 (22); 91 (41); 71 (13); 44 (10). Anal. Calcd for C₁₆H₁₉N₇O: 325.1649. Found: 325.1647.

C, 59.06; H, 5.89; N, 30.13. Found: C, 59.29; H, 6.07; N, 29.81. HRMS: Calcd for $C_{16}H_{19}N_7O$: 325.1649. Found: 325.1647.

4-Amino-3-benzoylamino-6-dimethylamino-1-methylpyrazolo[3,4-*d*]pyrimidine (6g) (85.7%). mp 138°C (ethyl acetate). IR (KBr): 3320, 3165 (NH); 1670 (C=O); 1627, 1600, 1580, 1549 (C=C, C=N); 1393; 1342; 791; 706. 1H -NMR (250.13 MHz, $CDCl_3$): δ = 3.20 (s, 6H, $N(CH_3)_2$); 3.71 (s, 3H, NCH_3); 6.29 (s, 2H, NH_2); 7.46-7.59 (m, 3H, H-3', 4'); 7.95 (d, J = 8.5 Hz, 2H, H-2'); 8.89 (s, 1H, CONH). ^{13}C -NMR (62.89 MHz, $CDCl_3$): δ = 32.7 (-, NCH_3); 37.1 (-, $N(CH_3)_2$); 89.1 (+, C-3a); 127.6 (-, C-2'); 128.8 (-, C-3'), 129.4 (-, C-2'); 132.6 (-, C-4'), 133.3 (+, C-1'); 137.0 (+, C-3); 157.5 (+, C-7a); 158.5 (+, C-4); 161.6 (+, C-6); 166.9 (+, CONH). MS m/z (%): $[M+1]^+$: 312 (21); M^+ : 311 (96); 296 (17); 282 (21); 105 (100); 77 (65); 71 (10); 44 (7). HRMS: Calcd for $C_{15}H_{17}N_7O$: 311.1495. Found: 311.1495.

4-Amino-6-dimethylamino-1-methyl-3-[(3-nitrobenzoyl)amino]pyrazolo[3,4-*d*]pyrimidine (6h) (35.6%). mp 255°C (ethyl acetate). IR (KBr): 3437, 3247 (NH); 1670 (C=O); 1602, 1570, 1529 (C=C, C=N); 1395; 1263; 789; 716. 1H -NMR (250.13 MHz, $DMSO-d_6$): δ = 3.13 (s, 6H, $N(CH_3)_2$); 3.70 (s, 3H, NCH_3); 6.73 (s, 2H, NH_2); 7.83 (t, J = 8.1 Hz, H-5'); 8.45 (q, J = 8.0 Hz, 2H, H-4', 6'); 8.86 (s, 1H, H-2'); 11.01 (s, 1H, CONH). ^{13}C -NMR (90.56 MHz, $DMSO-d_6$): δ = 32.5 (-, NCH_3); 36.6 (-, $N(CH_3)_2$); 89.8 (+, C-3a); 122.9 (-, C-2'); 126.3 (-, C-4'), 130.1 (-, C-5'); 134.3 (-, C-6'), 135.0 (+, C-1'); 136.7 (+, C-3); 147.6 (+, C-3'); 156.5 (+, C-7a); 157.5 (+, C-4); 161.2 (+, C-6); 164.8 (+, CONH). MS m/z (%): $[M+1]^+$: 357 (20); M^+ : 356 (100); 341 (24); 327 (26); 234 (10); 150 (33); 104 (25); 76 (22); 71 (15); 44 (11). HRMS: Calcd for $C_{15}H_{16}N_8O_3$: 356.1346. Found: 356.1347.

General procedure for the preparation of 8a-c:

A solution of *N,N*-dimethylformamide dimethyl acetal (7) 1.2 g (10 mmol) and corresponding substituted 4-aminopyrazolo[3,4-*d*]pyrimidine (6a-c) (0.5 mmol) in absolute toluene (10 mL) was refluxed for 6 h. After removal of the solvent the residue was chromatographed on a silica column (70-230 mesh) using acetone/ethyl acetate (1:1) as eluent to give 8a-c.

6-Dimethylamino-4-dimethylaminoazomethino-3-[(4-methoxybenzoyl)amino]-1-methylpyrazolo[3,4-*d*]pyrimidine (8a) (80.8 %). mp 210°C (acetone). IR (KBr): 3347 (NH); 1671 (C=O); 1642, 1602, 1570, 1542 (C=C, C=N); 1398; 1253. 1H -NMR (360 MHz, $DMSO-d_6$): δ = 2.85, 3.12 (2s, 6H, $N(CH_3)_2$ azometh.); 3.17 (s, 6H, $N(CH_3)_2$); 3.71 (s, 3H, NCH_3); 3.83 (s, 3H, OCH_3); 7.04 (d, J = 8.9 Hz, 2H, H-3'); 7.93 (d, J = 8.9 Hz, 2H, H-2'); 8.76 (s, 1H, $NCHN$); 9.88 (s, 1H, CONH). ^{13}C -NMR (90.56 MHz, $DMSO-d_6$): δ = 32.4 (-, NCH_3); 34.4, 40.6 (2-, $N(CH_3)_2$ azometh.); 36.8 (-, $N(CH_3)_2$); 55.5 (-, OCH_3); 94.5 (+, C-3a); 113.6 (-, C-3'); 126.3 (+, C-1'); 129.2 (-, C-2'); 139.4 (+, C-3); 156.4 (+, C-7a); 156.7 (-, $NCHN$); 161.3, 161.7 (2+, C-4, 6); 161.9 (+, C-4'); 163.8 (+, CONH). MS m/z (%): $[M+1]^+$: 397 (17); M^+ : 396 (73); 381 (10); 353 (9); 135 (100); 77 (9); 44 (7); 42 (9). HRMS: Calcd for $C_{19}H_{24}N_8O_2$: 396.2021. Found: 396.2020.

6-Dimethylamino-4-dimethylaminoazomethino-3-[(furan-2-carbonyl)amino]-1-

methylpyrazolo[3,4-*d*]pyrimidine (8b) (51.7 %). mp 221-223°C (chloroform). IR (KBr): 3537, 3434, 3307 (NH); 1675 (C=O); 1643, 1611, 1570, 1544 (C=C, C=N); 1328; 1095. ¹H-NMR (360 MHz, CDCl₃): δ= 3.21 (s, 9H, N(CH₃)₂, NCH₃azometh.); 3.28 (s, 3H, NCH₃azometh.); 3.82 (s, 3H, NCH₃); 6.53 (t, J= 3.6 Hz, 1H, H-4'); 7.27 (t, J= 4.0 Hz, 1H, H-3'); 7.33 (t, J= 1.0 Hz, 1H, H-5'); 8.86 (s, 1H, NCHN); 10.07 (s, 1H, CONH). ¹³C-NMR (90.56 MHz, CDCl₃): δ= 32.9 (-, NCH₃); 34.8, 41.5 (2-, N(CH₃)₂azometh.); 37.2 (-, N(CH₃)₂); 92.8 (+, C-3a); 112.7 (-, C-4'); 115.3 (-, C-3'); 140.3 (+, C-3); 143.5 (-, C-5'); 148.2 (+, C-2'); 153.8 (+, C-7a); 156.1 (+, C-4); 156.6 (-, NCHN); 161.6 (+, C-6); 162.2 (+, C-4'); 163.8 (+, CONH). MS m/z (%): [M+1]⁺: 357 (24); M⁺: 356 (100); 341 (28); 312 (14); 232 (10); 95 (58); 57 (10); 44 (20); 42 (23). HRMS: Calcd for C₁₆H₂₀N₈O₂: 356.1710. Found: 356.1711.

6-Dimethylamino-4-dimethylaminoazomethino-1-methyl-3-[(thiophene-2-carbonyl)amino]pyrazolo[3,4-*d*]pyrimidine (8c) (65.6%). mp 214°C (chloroform). IR (KBr): 3320 (NH); 1666 (C=O); 1636, 1603, 1570, 1534 (C=C, C=N); 1421; 1399; 797; 736. ¹H-NMR (360 MHz, CDCl₃): δ= 3.20, 3.21 (2s, 12H, N(CH₃)₂, N(CH₃)₂azometh.); 3.85 (s, 3H, NCH₃); 7.07 (dd, J= 5.0, 3.7 Hz, 1H, H-4'); 7.49 (dd, J= 5.0, 1.3 Hz, 1H, H-5'); 7.67 (dd, J= 3.7, 1.1 Hz, 1H, H-3'); 8.86 (s, 1H, NCHN); 9.52 (s, 1H, CONH). ¹³C-NMR (90.56 MHz, CDCl₃): δ= 33.0 (-, NCH₃); 35.4, 41.6 (2-, N(CH₃)₂azometh.); 37.3 (-, N(CH₃)₂); 92.7 (+, C-3a); 127.5 (-, C-4'); 128.8 (-, C-5'); 130.4 (-, C-3'); 139.1 (+, C-3); 140.4 (+, C-2'); 156.2 (+, C-7a); 157.1 (-, NCHN); 157.7 (+, C-4); 161.7 (+, C-6); 162.1 (+, CONH). MS m/z (%): [M+1]⁺: 373 (22); M⁺: 372 (100); 357 (29); 343 (15); 329 (9); 111 (54); 46 (8). HRMS: Calcd for C₁₆H₂₀N₈OS: 372.1480. Found: 372.1439.

4-Amino-6-dimethylamino-3-dimethylaminoazomethino-1-methylpyrazolo[3,4-*d*]pyrimidine (9a) and **3-Amino-6-dimethylamino-4-dimethylaminoazomethino-1-methylpyrazolo[3,4-*d*]pyrimidine (9b)**:

A solution of **4** (0.41 g, 2 mmol) and *N,N*-dimethylformamide dimethyl acetal (**7**) (0.24 g, 2 mmol) in absolute toluene (20 mL) was stirred at 90°C for 7 h. After removal of the solvent the residue was chromatographed on a silica column (70-230 mesh) using ethyl acetate/acetone (1:1) as eluent. Two fractions (R_f= 0.31 (**9a**), R_f= 0.26 (**9b**)) were obtained as **9a** and **9b** respectively.

9a: - 0.33 g (63.0%). mp 193°C (chloroform). IR (KBr): 3425, 3312, 3188 (NH); 1630, 1593, 1545 (C=C, C=N); 1427; 1386; 1331; 1105; 982; 796. ¹H-NMR (250.13 MHz, CDCl₃): δ= 3.04 (s, 6H, N(CH₃)₂azometh.); 3.17 (s, 6H, N(CH₃)₂); 3.72 (s, 3H, NCH₃); 5.59 (s, 2H, NH₂); 8.25 (s, 1H, NCHN). ¹³C-NMR (62.89 MHz, CDCl₃): δ= 32.4 (-, NCH₃); 37.2 (-, N(CH₃)₂); 34.3, 40.4 (2-, N(CH₃)₂azometh.); 89.0 (+, C-3a); 151.7 (+, C-3); 153.9 (-, NCHN); 157.1 (+, C-7a); 158.7 (+, C-4); 162.5 (+, C-6). MS m/z (%): [M+1]⁺: 263 (20); M⁺: 262 (100); 247 (31); 233 (12); 218 (13); 131 (10); 46 (27); 44 (12). Anal. Calcd for C₁₁H₁₈N₈: C, 50.37; H, 6.92; N, 42.72. Found: C, 50.54; H, 6.95; N, 42.66.

9b: -90 mg (17.2%). mp 198°C (chloroform). IR (KBr): 3433, 3280, 3185 (NH); 1636, 1595, 1557 (C=C, C=N); 1419; 1386; 1328; 1286; 1099; 801. ¹H-NMR (250.13 MHz, CDCl₃): δ= 3.11, 3.13 (2s, 6H,

$N(\text{CH}_3)_2$ azometh.); 3.20 (s, 6H, $N(\text{CH}_3)_2$); 3.65 (s, 3H, NCH_3); 4.54 (s, 2H, NH_2); 8.79 (s, 1H, NCHN). ^{13}C -NMR (62.89 MHz, CDCl_3): δ = 32.2 (-, NCH_3); 37.2 (-, $N(\text{CH}_3)_2$); 37.8, 41.1 (2-, $N(\text{CH}_3)_2$ azometh.); 92.0 (+, C-3a); 148.6 (+, C-3); 156.6 (-, NCHN); 157.3 (+, C-7a); 162.4 (+, C-6, C-4). MS m/z (%): $[\text{M}+1]^+$: 263 (15); M^+ : 262 (100); 247 (36); 233 (13); 218 (19); 175 (12); 131 (7); 46 (13); 44 (11); 42 (14). Anal. Calcd for $\text{C}_{11}\text{H}_{18}\text{N}_8$: C, 50.37; H, 6.92; N, 42.72. Found: C, 50.39; H, 7.20; N, 42.56. HRMS: Calcd for $\text{C}_{11}\text{H}_{18}\text{N}_8$: 262.1654. Found: 262.1654.

6-Dimethylamino-3,4-bis[(dimethylamino)azomethino]-1-methylpyrazolo[3,4-*d*]pyrimidine (10):

A solution of **4** (0.21 g, 1 mmol) and *N,N*-dimethylformamide dimethyl acetal (**7**) (0.60 g, 5 mmol) in absolute toluene (8 mL) was refluxed for 15 h. Then the mixture was cooled to -20°C overnight, the light yellow crystals were filtered and washed with ether to give 0.27 g **10** (84.1%). mp $194\text{--}197^\circ\text{C}$ (chloroform). IR (KBr): 1640, 1619, 1582, 1534 (C=C, C=N); 1484; 1379; 1224; 1102; 1033; 970; 800. ^1H -NMR (360 MHz, CDCl_3): δ = 3.02, 3.07 (2s, 6H, $N(\text{CH}_3)_2$ azometh.); 3.13, 3.16 (2s, 6H, $N(\text{CH}_3)_2$ azometh.); 3.23 (s, 6H, $N(\text{CH}_3)_2$); 8.33 (s, 1H, NCHN); 8.63 (s, 1H, NCHN). ^{13}C -NMR (90.56 MHz, CDCl_3): δ = 32.5 (-, NCH_3); 34.2, 40.2 (2-, $N(\text{CH}_3)_2$ azometh.); 34.9, 40.4 (2-, $N(\text{CH}_3)_2$ azometh.); 37.3 (-, $N(\text{CH}_3)_2$); 94.2 (+, C-3a); 152.3 (+, C-3); 156.3 (-, NCHN); 157.7 (-, NCHN); 157.9 (+, C-7a); 161.6 (+, C-4); 163.5 (+, C-6). MS m/z (%): $[\text{M}+1]^+$: 318 (23); M^+ : 317 (100); 302 (45); 288 (15); 273 (19); 246 (11); 230 (12); 159 (11); 46 (69); 44 (31); 42 (25). Anal. Calcd for $\text{C}_{14}\text{H}_{23}\text{N}_9$: C, 52.98; H, 7.30; N, 39.72. Found: C, 53.18; H, 7.42; N, 39.59.

1,5-Dihydro-7-dimethylamino-5*H*-1-methyl-4-(4-methoxyphenyl)-1,2,3,5,6,8-

hexaazaacenaphthylene (11): A solution of **8a** (0.17 g, 0.5 mmol) in POCl_3 (4 mL, 43 mmol) was refluxed for 3.5 h. After removal of POCl_3 under reduced pressure, about 10 g of ice was added. The mixture was neutralized with sodium hydrogen carbonate to pH = 7. The precipitates were filtered and chromatographed on a silica column (70-230 mesh) using ethyl acetate as eluent to give 10 mg of **11** (6.2%). mp 140°C (chloroform). IR (KBr): 3372, 3211 (NH); 1729; 1647, 1608, 1545, 1513 (C=C, C=N); 1394; 1309; 1255; 1178; 801; 740. ^1H -NMR (360 MHz, CDCl_3): δ = 3.17 (s, 6H, $N(\text{CH}_3)_2$); 3.84, 3.87 (2s, 6H, NCH_3 , OCH_3); 5.54 (s, 1H, NH); 6.96 (d, J = 8.9 Hz, 2H, H-3'); 7.89 (d, J = 8.9 Hz, 2H, H-2'). ^{13}C -NMR (90.56 MHz, CDCl_3): δ = 33.6 (-, NCH_3); 37.9 (-, $N(\text{CH}_3)_2$); 55.4 (-, OCH_3); 96.5 (+, C-8b); 114.3 (-, C-3'); 126.4 (+, C-1'); 128.8 (-, C-2'); 152.1 (+, C-2a); 154.5 (+, C-4); 155.2 (+, C-8a); 155.5 (+, C-5a); 162.3 (+, C-7); 165.5 (+, C-4'). MS m/z (%): $[\text{M}+1]^+$: 324 (21); M^+ : 323 (100); 308 (25); 294 (19); 279 (14); 161 (8); 134 (17); 106 (7); 77 (5); 44 (7); 43 (8). HRMS: Calcd for $\text{C}_{16}\text{H}_{17}\text{N}_7\text{O}$: 323.1493. Found: 323.1491.

7-Dimethylamino-1-methyl-1,3,5-trihydro-1,2,3,5,6,8-hexaazaacenaphthylene-4(3,5*H*)-one (12):

A solution of ethyl chloroformate (0.16 g, 1.5 mmol) in water-free acetonitrile (20 mL) was dropped at rt within 30 min to the mixture of **4** (0.21 g, 1 mmol), triethyl amine (0.3 mL, 2.25 mmol) and water-free acetonitrile (50 mL). The mixture was stirred for a week and then the solvent was removed under reduced pressure. The residue was chromatographed on a silica column (70-230 mesh) using ethyl acetate/acetone

(1:1) as eluent to give 55 mg **12** (23.6%). mp > 230°C (acetone). IR (KBr): 3348, 3240 (NH); 1719 (C=O); 1634, 1596, 1546 (C=C, C=N); 1395; 1310; 788. ¹H-NMR (360 MHz, DMSO-d₆): δ= 3.12 (s, 6H, N(CH₃)₂); 3.66 (s, 3H, NCH₃); 7.09 (s, 1H, CONH); 10.04 (s, 1H, CONH). ¹³C-NMR (90.56 MHz, DMSO-d₆): δ= 32.4 (-, NCH₃); 36.7 (-, N(CH₃)₂); 87.2 (+, C-8b); 138.2 (+, C-2a); 154.0 (+, C-5a); 156.4 (+, C-8a); 157.5 (+, C-7); 161.3 (+, C=O). MS m/z (%): [M+1]⁺: 234 (11); M⁺: 233 (83); 218 (42); 207 (100); 204 (34); 192 (39); 178 (22); 164 (29); 147 (19); 71 (32); 57 (11); 44 (34); 43 (34); 42 (26). HRMS: Calcd for C₉H₁₁N₇O: 233.1026. Found: 233.1027.

ACKNOWLEDGEMENTS

Generous support of this work by BASF AG, BAYER AG, HOECHST AG, Verband der Chemischen Industrie -Fonds der Chemie-, and Deutsche Forschungsgemeinschaft is gratefully acknowledged. We are indebted to Dr. W. Kramer and Mrs. U. Hertle for recording and discussing NMR spectra, to Mr. H. Rudy and Mr. P. Weyrich for mass spectra and elemental analysis.

REFERENCES

1. a) T. L. Cairns, R. A. Carboni, D. D. Coffman, V. A. Engelhardt, R. E. Heckert, E. L. Little, E. G. McGeer, B. C. McKusick, W. J. Middleton, R. M. Scribner, C. W. Theobald and H. E. Winberg, *J. Am. Chem. Soc.*, 1958, **80**, 2775; b) W. J. Middleton and V. A. Engelhardt, *J. Am. Chem. Soc.*, 1958, **80**, 2788.
2. A. Hotzel, R. Neidlein, R. Schulz and A. Schweig, *Angew. Chem.*, 1980, **92**, 751; *Angew. Chem., Int. Ed. Engl.*, 1980, **19**, 739.
3. D. Kikelj, *Ph. D. Thesis*, University Heidelberg, 1988.
4. R. Neidlein and Z. Wang, *Synth. Commun.*, 1997, **27**, 1223.
5. R. Neidlein and Z. Wang, *Heterocycles*, 1997, **45**, 1509.
6. Z. Wang and R. Neidlein, *Tetrahedron*, 1998, **54**, 9903.
7. M. Tisler, *Heterocycles*, 1983, **20**, 1591 and literature cited therein.
8. Z. Wang and R. Neidlein, *Heterocycles*, 1998, **48**, 1923.

Received, 14th September, 1998